Programme Structure 2022
Opening: Monday October 31, 2022
| 10:00 - | Optional Tour, Limassol | |
| 15:00 - | Registration desk Open | |
| 15:00 - | Poster Set-up | |
| 17:30 - 18:30 | Welcome Reception | |
| 18:45 - 19:45 | Presentation “Rare Disease Patient story” | |
| 20:00 - |
Opening Dinner |
Session 1 : Tuesday November 1, 2022
Advancing plasma therapeutics from early research to clinical trials
Chair: Sami Chtourou, K2C-BIOPHARM
| 08:55– 09:00 | Introductary remarks | |
| 09:00 – 09:10 | Sami Chtourou (K2C-BIOPHARM), Session chair introduction | |
| 09:10 – 09:45 | Andy Bailey (ViruSure) Next Generation Sequencing: Applications of this powerful tool for adventitious virus testing in biological products | |
| 09:45 – 10:20 | Christoph Bausch ( SAb Biotherapeutics), Plasma fractionation and downstream processing of human polyclonal antibodies from the DiversitAbTM platform. | |
| 10:20 - 10:50 | Coffee break | |
| 10:50 – 11:25 | Christoph Bausch ( SAb Biotherapeutics), Efficacy and safety of SAb-185, a novel SARS-CoV-2 immunotherapeutic: a Phase 1/1b and DAIDS NIAID ACTIV2 sponsored adaptive Phase 2/3 clinical trial | |
| 11:25 – 12:00 |
Fabian Kaesermann ( CSL), Next-Generation Fc Receptor–Targeting Biologics for Autoimmune Diseases |
|
| 12:00 – |
End of the session |
|
| 12:15 – 16:00 |
Networking tour including lunch |
Session 2: Tuesday November 1, 2022
Safety, Quality and Regulatory aspects of plasma fractionation
Panel facilitator: Beatrice Biebuyck, Takeda
| 16:30 – 17:30 |
Panel discussion Dr. Thomas R. Kreil Head of Pathogen Safety at Takeda Dr. Dorothy Scott Branch Chief, Plasma Derivatives Branch, Division of plasma Dr. Dominika Misztela, Senior. Director, Head of Global Regulatory Policy Saleh Yusuf MBA, LSSBB, Director of North America Logistics, Kedrion Biopharma Inc |
|
| 17:30 – 18:00 | Coffee break | |
| 18:00 – 19:30 | Panel discussion continued | |
| 19:45 – | Dinner Buffet |
Session 3: Wednesday November 2, 2022
Novel technologies and solutions for plasma fractionation
Chair: Merche Faro, Grifols
| 08:55– 09:00 | Introductary remarks | ||
| 09:00 - 09:10 | Merche Faro (Grifols) Session chair introduction | ||
| 09:10 - 09:45 |
Lynne Deakin (3M Company) Next Generation Bioprocessing Using Novel Materials and Ligand Chemistries |
||
| 09:45 – 10:20 | Gerhard Poelsler (Biotest) Virus inactivation by UV-C irradiation of plasma proteins | ||
| 10:20 – 10:50 | Coffee break | ||
| 10:50 – 11:25 | Jan Kyhse-Andersen (CHRETO) Novel Dual Affinity Protein technology provide 80% increase in yield of IVIG |
||
| 11:25 – 12:00 | Patrick Gregory (CSL Behring) Process Knowledge reboot: Applying QbD to legacy plasma products to modernize PPQ, Quality Management, and the regulatory dossier | ||
| 12:00 – | End of the session, Lunch break | ||
| 15:00 - 17:00 | Poster Session | ||
| 17.00 - 18.00 | Focus lecture Dr Kostiantyn Yefymenko, (CEO of Biopharma Plasma in Ukraine) "The Ukraine model works" |
Session 4 : Thursday November 3, 2022
Plasma 4.0 – digital transformation of the plasma business and manufacturing
Chair: Barbara Kalina, CSL Behring
| 09:00 - 09:10 | Barbara Kalina (CSL Behring) Session chair introduction | |
| 09:10 - 09:45 | Paul Sylvain (Takeda) Yield optimization of plasma fraction purification using mechanistic chromatography modeling |
|
| 09:45 - 10:20 | Pushpa Kotharu (CSL Behring) Technology Transfer during the COVID pandemic: Leveraging Communication Platforms and Mixed Reality |
|
| 10:20 - 10:50 | Coffee break | |
| 10:50 – 11:25 | Patrick Gavit (Takeda) Overcoming manufacturing challenges for the super orphan plasma-derived drug BabyBIG® used to treat infant botulism | |
| 11:25 - 12:00 |
Richard Weidemann (CSL Behring) Base Fractionation – Next Generation |
|
| 12:00 – |
End of the session, Lunch break |
Session 5 : Thursday November 3, 2022
Future perspectives on the plasma business and market
Chair: Eric Youssef, Cytiva
| 14:00 - 14:10 | Eric Youssef (Cytiva) Session chair introduction | |
| 14:10 - 14:45 | Patrick Robert (Marketing Research Bureau) The impact of Covid- 19 and other events on the plasma fractionation industry - Historical Perspective and Lessons Learned (or Not) |
|
| 14:45 – 15.20 | Jan Bult (JMB Consultancy BV) Multiple challenges impact future perspectives. |
|
| 15-20 - 15:50 | Cofee break | |
| 15:50 - 16:25 | Leni Von Bonsdorff (IPFA) How the plasma supply can meet the needs for plasma-derived medicines and bring value to the public health system |
|
| 16:25- 17:00 |
John Curling (JCC AB) What can we expect from the plasma fractionation industry in the future? |
|
| 17.00 |
End of the session |
|
| 18:00- 19:00 |
Reception |
|
| 19:00- | Final conference dinner | |
| End of Conference |